Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

March 30, 2026

Availability Update for the Carpuject® Syringe System

Dear Valued Customer,

Pfizer U.S. Hospital & Biosimilars is committed to providing important supply information so that you can plan for patient care. We know the importance of our ready-to-use sterile injectables to our customers and for Carpuject® platform medications while the overall market supply availability is low. As such, we are pleased to share that multiple Carpuject® products will become available, beginning in mid-April. The appendix includes a list of the Carpuject® products slated for market release.

We hold our products to the highest quality standards, which is why, out of an abundance of caution and in collaboration with the FDA—in tandem with the release of these Carpuject® products—we are also issuing an Important Drug Warning Letter (IDWL). We were made aware of an injection molding defect at the tip of the needle sheath, with the potential to manifest as a hole, potentially impacting certain lots as outlined in the appendix of the IDWL. **Please note that this is not a product recall, and it is not a manufacturing site warning letter.**

The overall risk to patients is low and no safety signals or product quality complaints have been identified. Customers should continue their standard practice of visually examining Carpuject® units and should discard any unit showing a hole in the tip of the needle sheath prior to administration. **Healthcare providers can continue to administer those that do not show a hole at the tip of the needle sheath.**

For product with a confirmed hole at the tip of the needle sheath, standard credit processes apply. Please contact Pfizer Customer Service at 844-646-4398 or PICustomerService@Pfizer.com with the NDC number, lot number, and quantity for assistance.

Pfizer remains committed to the Carpuject® Syringe System and is proud of our many teams who have worked diligently to bring supply of these important medications back to the market. The Carpuject® Syringe System is a critical part of our Hospital portfolio and one we continue to invest in for a sustainable future. We invite you to join us for our upcoming Customer Webinar on April 15 or 16 where we will discuss this topic, and other manufacturing and supply availability updates. Please speak with your Pfizer Sales Representative for more information and to register.

Pfizer will continue to make regular supply updates and we encourage you to check our Availability Report, updated frequently and accessible PfizerHospitalUS.com, for the latest information on product status.

Regards,

Roman Savchenko
Director, U.S. Marketing, Pain Management
U.S. Commercial, Pfizer Global Hospital & Biosimilars

Appendix:

Carpuject® Syringe System Products
Buprenorphine Hydrochloride Injection, USP, CIII
Diazepam Injection, USP, CIV
Demerol® (meperidine hydrochloride injection, USP, CII)
Heparin Sodium Injection, USP
Hydromorphone Hydrochloride Injection, USP, CII
Labetalol Hydrochloride Injection, USP
Lorazepam Injection, USP, CIV
Morphine Sulfate Injection, USP, CII (Preservative and Antioxidant Free)
Naloxone Hydrochloride Injection, USP

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Pfizer Global Hospital & Biosimilars